Pages that link to "Item:Q2803513"
From MaRDI portal
The following pages link to Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance (Q2803513):
Displaying 11 items.
- Frequentist-Bayesian Monte Carlo test for mean vectors in high dimension (Q679574) (← links)
- Type I error probability spending for post-market drug and vaccine safety surveillance with Poisson data (Q1657816) (← links)
- Continuous readout versus titer-based assays of influenza vaccine trials: sensitivity, specificity, and false discovery rates (Q2003708) (← links)
- Complementary hypotheses in safety surveillance (Q4965656) (← links)
- Nearly optimal truncated group sequential test on binomial proportions (Q5085028) (← links)
- Two-sample two-stage and purely sequential methodologies for tests of hypotheses with applications: comparing normal means when the two variances are unknown and unequal (Q5379333) (← links)
- Exact conditional maximized sequential probability ratio test adjusted for covariates (Q5379334) (← links)
- A seasonality-adjusted sequential test for vaccine safety surveillance (Q6589304) (← links)
- Alpha spending for historical versus surveillance Poisson data with CMaxSPRT (Q6625629) (← links)
- The person-time ratio distribution for the exact monitoring of adverse events: historical vs surveillance Poisson data (Q6626852) (← links)
- Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data (Q6627990) (← links)
